Skip to main content
Premium Trial:

Request an Annual Quote

Immunexpress Nabs $599K BARDA Contract to Develop Sepsis Test for Coronavirus Patient Triage

NEW YORK ─ Molecular diagnostics firm Immunexpress said Tuesday that it has been awarded a grant of up to $599,549 by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to develop its host response sepsis test, SeptiCyte Rapid, as a triage tool to help identify SARS-CoV-2 patients with an elevated risk for viral or secondary bacterial sepsis.

SeptiCyte Rapid is a gene expression assay that uses reverse-transcription PCR to quantify the relative expression levels of host response genes isolated from whole blood.

With the BARDA funding, Seattle-based Immunexpress expects to validate its test as a triage tool and pursue US Food and Drug Administration Emergency Use Authorization.

"The COVID-19 pandemic has exacerbated the need for rapid identification and triage of COVID-19 patients at risk of sepsis," Rolland Carlson, CEO of Immunexpress, said in a statement. "Equipping clinicians with the best tools to manage patients quickly, safely, and appropriately is the first step in addressing the high mortality rate associated with sepsis infection in COVID-19 patients."

Immunexpress received the CE-IVD mark for SeptiCyte Rapid in March and announced a long-term commercialization partnership with Mechelen, Belgium-based Biocartis in Europe. The diagnostic test runs on the Biocartis Idylla system.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.